Growth Disorders

Shanghai, China, September 21, 2026 Abbisko Therapeutics has announced positive preliminary results from a Phase 2 clinical study evaluating...

PALO ALTO, Calif. — September 9, 2026 BridgeBio Pharma, Inc. presented new exploratory analyses from the Phase 3 PROPEL...

SAN RAFAEL, Calif., June 16, 2026 BioMarin Pharmaceutical Inc. announced new clinical findings from its approved therapy VOXZOGO® (vosoritide)...